Real-time CGM for type 2 diabetes
Type 2 diabetes is a complex condition in which the body may be able to produce insulin, but the cells can’t use it effectively. Some people with type 2 diabetes can control glucose levels with lifestyle changes, while others need to take insulin or other medications.
Like people with type 1 diabetes, those living with type 2 may need to check their glucose levels regularly. Real-time Continuous Glucose Monitoring (CGM) systems provide automatic, continuous readings without finger pricks* or scanning.
Using CGM can aid patients with type 2 diabetes in better understanding their glucose levels, resulting in more informed lifestyle decisions,3 improving glycaemic control1-4 and therefore, decreasing the risk of complications.6-8
The better way to manage your type 2 diabetes
Goodbye finger pricks.* Hello glucose numbers on the go.
With real-time CGM, you can effortlessly see where your glucose levels are at and where they’re heading, so you can make informed treatment decisions, in the moment. And no more sore fingers – zero finger pricks* are required.
Discover 'Aha' moments in your dailyactivities and habits
Real-time CGM helps you understand the impact of food, physical activity and medication on your glucose levels. It provides key trends and data that give you and your health care team the full picture to adjust your diet or medication.
Confident diabetes management morning, noon and night
Customisable glucose alerts that can be switched on by the user notify you whether your glucose levels are too high or too low. With real-time CGM you can stay one step ahead of your type 2 diabetes.
Safeguarding against type 2 diabetescomplications
Type 2 patients can have more control¶ over their health outcomes with real-time CGM. The use of CGM helps support better glycaemic control1-4 and therefore proactively mitigating risks associated with type 2 diabetes, such as cardiovascular issues, neuropathy, and kidney problems.6-8
Real-time CGM is proven to improve outcomes
for people with Type 2 diabetes
Reduce Hypoglycemia1,5
Increase time in range††,1,5
Decrease HbA1C1,2,4
Healthier lifestyle4,5
Discreet diabetes management
Only Dexcom sensors can be worn in multiple wear locations.‖
Back of the arm, abdomen, and upper buttocks
They automatically record glucose levels without input from the wearer, such as scanning, and work beneath clothing – perfect for people who prefer to manage their diabetes privately.
Easy and convenient diabetes technology
Our CGM systems are easy to use.**,9 With one push of a button, your sensor is inserted – in fact 90% of users report a painless insertion. And our in-app onboarding will get you started in just a few clicks. Easy, right?
Designed to help show small and big wins
Our unique Delay 1st high alert allows you to tailor the alerts to your meal and insulin schedule. As you adjust your routine, our Clarity Card shows you how changes to your life style may have a significant impact.# That’s smarter diabetes management.
The Dexcom ONE+ Continous Glucose Monitoring System is available for purchase.
From 1st January 2022, the Estonian Health Insurance Fund will reimburse the Dexcom ONE Continuous Glucose Monitoring System for people with Type 1 diabetes.
“With Dexcom, I’m more calm. I did a lifestyle change on food, I’m losing weight, I’m exercising. Everything!”
Rick F., Dexcom, Type 2 Warrior
The featured Warrior is a sponsored spokesperson of Dexcom.
References:
* Finger pricks required for diabetes treatment decisions if symptoms or expectations do not match readings.
† Dexcom ONE User Guides.
‡ Discuss with your HCP on how to use CGM information to manage diabetes.
§ For a list of compatible smart devices, please visit www.dexcom.com/compatibility.
‖ Dexcom ONE and Dexcom ONE+ are approved for wear on the arm and abdomen, and ages 2-17 for Dexcom ONE and 2-6 for Dexcom ONE+ can also wear their sensor on the upper buttocks.
# An internet connection is required while uploading to Dexcom Clarity.
**Results obtained with Dexcom G6 study, which uses the same applicator as Dexcom ONE.
* Finger pricks required for diabetes treatment decisions if symptoms or expectations do not match readings.
† Dexcom ONE User Guides.
‡ Discuss with your HCP on how to use CGM information to manage diabetes.
§ For a list of compatible smart devices, please visit www.dexcom.com/compatibility.
‖ Dexcom ONE and Dexcom ONE+ are approved for wear on the arm and abdomen, and ages 2-17 for Dexcom ONE and 2-6 for Dexcom ONE+ can also wear their sensor on the upper buttocks.
# An internet connection is required while uploading to Dexcom Clarity.
**Results obtained with Dexcom G6 study, which uses the same applicator as Dexcom ONE.
1. Grace TG, et al. Diabetes Technol Ther. 2022;24(1):26-31.
2. Martens T. et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial.JAMA. 2021;325(22):2262-2272.
3. Ehrhardt N, Al Zaghal E. Continuous Glucose Monitoring As a Behavior Modification Tool. Clin Diabetes 2020;38(2):126-131.
4. Majithia AR, et al. Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor-Driven Virtual Diabetes Clinic: Prospective Trial. J Med Internet Res. 2020 Aug 28;22(8):e21778.
5 Polonsky et al. Diabetes Care. 2018;40(6):736736-741
6 Lind et al. Diabetes Care 2021;44:2231–2237.
7 UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.
8 Stratton et al. NMG. 2000;321:405-12.
9 Dexcom, Data on File, 2022.
2. Martens T. et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial.JAMA. 2021;325(22):2262-2272.
3. Ehrhardt N, Al Zaghal E. Continuous Glucose Monitoring As a Behavior Modification Tool. Clin Diabetes 2020;38(2):126-131.
4. Majithia AR, et al. Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor-Driven Virtual Diabetes Clinic: Prospective Trial. J Med Internet Res. 2020 Aug 28;22(8):e21778.
5 Polonsky et al. Diabetes Care. 2018;40(6):736736-741
6 Lind et al. Diabetes Care 2021;44:2231–2237.
7 UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.
8 Stratton et al. NMG. 2000;321:405-12.
9 Dexcom, Data on File, 2022.